The protocol described herein is designed to provide clinical evidence of the substantial equivalence of SmartPill GI Monitoring System (SP) to the Sitzmarks (Konsyl Pharmaceuticals, Easton, MD) radio-opaque markers (ROM). The trial will enroll symptomatic subjects who meet Rome III criteria (1) for chronic functional constipation.
The primary aim of this study is to assess the equivalence of SP to ROM through characterization of device agreement using SP cutoffs for colonic and whole gut transit (59hrs and 73 hrs respectively) derived from the above mentioned study. The cutoffs are derived from the 95th percentile of the healthy subjects in the study. Demonstration of agreement will also serve to validate these SP cutoffs. Device agreement will be evaluated by comparing the percentage of subjects identified with slow transit versus normal transit with SmartPill to the percentage of subjects identified with slow versus normal transit with ROM in the study population. The colonic transit time results will serve as the primary measure for slow versus normal transit for SmartPill. For ROM test we will employ the Metcalf protocol which provides a measure of whole gut transit to compare the SmartPill results to. Additionally, we will characterize gastric emptying and small bowel transit time of the SmartPill in this population. The SmartPill test will be administered simultaneously with ROM. A modified Metcalf procedure will be employed for characterization of slow transit by ROM. The SmartPill GI Monitoring System offers an alternative non-invasive method for characterizing disorders of the stomach. The system consists of an ingestible capsule that houses sensors for pH, temperature, and pressure, a receiver for receiving and storing signals from the capsule, and software for displaying data on a personal computer. The capsule samples at regular intervals and transmits the sensed pH, pressure, and temperature data to a portable receiver worn by the subject. After test completion, the recorded data is downloaded to a personal computer for subsequent evaluation. This trial is for subjects 18 years of age to 80 years of age.
Study Type
OBSERVATIONAL
Enrollment
210
University of Arizona Health and Sciences Ctr Southern Arizona VA HealthCare System
Tucson, Arizona, United States
WITHDRAWNCedars-Sinai Medical Center
Los Angeles, California, United States
Colonic Transit Time
Time frame: 4 days and 7 days
Determine regional gut (gastric, small bowel, colonic) transit times
Time frame: continuous time measure until caspule elimination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Iowa
Iowa City, Iowa, United States
COMPLETEDUniversity of Kansas Med Center
Kansas City, Kansas, United States
COMPLETEDMassachusetts General Hospital
Boston, Massachusetts, United States
COMPLETEDUniversity of Michigan Med Center
Ann Arbor, Michigan, United States
RECRUITINGJasper Clinic, Inc.
Kalamazoo, Michigan, United States
COMPLETEDMayo Clinic
Rochester, Minnesota, United States
COMPLETEDUniversity of Buffalo VA Medical Center
Buffalo, New York, United States
COMPLETEDUniversity of North Carolina Medical Center
Chapel Hill, North Carolina, United States
COMPLETED...and 3 more locations